| Dr Michael Anthony Griffey Ii, MD | |
|
1000 S 52nd St, Rogers, AR 72758-8610 | |
| (479) 271-9607 | |
| (479) 271-2133 |
| Full Name | Dr Michael Anthony Griffey Ii |
|---|---|
| Gender | Male |
| Speciality | Orthopaedic Surgery |
| Location | 1000 S 52nd St, Rogers, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366415010 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | E4084 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Anthony Griffey Ii, MD 1000 S 52nd St, Rogers, AR 72758-8610 Ph: (479) 271-9607 | Dr Michael Anthony Griffey Ii, MD 1000 S 52nd St, Rogers, AR 72758-8610 Ph: (479) 271-9607 |
News Archive
Participating in a brief intervention delivered by their peers in community settings can help reduce smoking among youth and young adults, a new study from a team of tobacco-cessation researchers shows.
Myriad Genetics, Inc. today announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer (TNBC) that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.
The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.
New research, headed by microbiologists from the University of Georgia, show for the first time that Salmonella – a widespread and often deadly bacterial pathogen – use molecular hydrogen to grow and become virulent.
› Verified 5 days ago
Mr. Dominic Amadeo Jacobelli, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 S 52nd St, Rogers, AR 72758 Phone: 479-271-9607 | |
Andreas J. Chen, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 S 52nd St, Rogers, AR 72758 Phone: 479-271-9607 Fax: 479-271-2133 | |
Trenden L Flanigan, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1000 S 52nd St, Rogers, AR 72758 Phone: 479-271-9607 Fax: 479-271-2133 | |
Charles Irving Jones Iii, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 S 52nd St, Mercy Clinic Orthopedics, Rogers, AR 72758 Phone: 479-271-9607 Fax: 479-271-2133 | |
Dr. John D Mertz, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1101 S Horsebarn Rd, Rogers, AR 72758 Phone: 479-271-9607 Fax: 479-271-2133 | |
Dr. Peter Tang, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 5511 Walsh Lane, Rogers, AR 72757 Phone: 479-750-7256 Fax: 479-750-7442 |